Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 7/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082988 | 0.89 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL5086450 | 0.84 | DNPH1 (0.38) | DNPH1FGFR1FGFR4P2RX7CCNE2 | |
| SCHEMBL5086075 | 0.74 | CYP3A4 (0.46) | FGFR1CYP3A4 | |
| SCHEMBL5082388 | 0.73 | ADK (0.31) | — | |
| SCHEMBL5086376 | 0.69 | PI4KA (0.44) | FGFR1CYP3A4 | |
| SCHEMBL5082287 | 0.69 | PI4KA (0.44) | FGFR1CYP3A4 | |
| SCHEMBL5086069 | 0.67 | PI4KA (0.43) | FGFR1CYP3A4 | |
| SCHEMBL5086440 | 0.64 | DNPH1 (0.35) | DNPH1FGFR1FGFR4P2RX7JAK2 | |
| SCHEMBL5925937 | 0.63 | FGFR1 (0.48) | FGFR1FGFR4P2RX7JAK2CCNE2 | |
| SCHEMBL6905254 | 0.63 | DNPH1 (0.42) | DNPH1FGFR1FGFR4P2RX7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | DNPH1 566/4885FGFR1 3600/4885FGFR4 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.